CK1 delta inhibitor

CK1 delta inhibitors are a class of therapeutic agents that target Casein Kinase 1 delta (CK1δ), a serine/threonine kinase encoded by the CSNK1D gene. CK1δ is a key regulator of several critical cellular processes, including the circadian clock, Wnt/β-catenin signaling, DNA damage response, and microtubule dynamics. In many cancers, including bladder and breast cancer, CK1δ is overexpressed and contributes to tumor progression, survival, and metastasis. Inhibition of CK1δ, achieved through small-molecule inhibitors or genetic approaches like short hairpin RNA (shRNA), has been shown to downregulate the Wnt/β-catenin pathway, trigger apoptosis via caspase activation, and inhibit epithelial-mesenchymal transition (EMT) by modulating markers such as E-cadherin, vimentin, snail, and slug. Research presented at AACR 2018 identifies CK1 delta as a potential therapeutic target for bladder cancer, where its inhibition significantly impairs cell viability and migration.